Search details
1.
Translating Germline Cancer Risk into Precision Prevention.
Cell
; 168(4): 566-570, 2017 02 09.
Article
in English
| MEDLINE | ID: mdl-28187278
2.
A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study.
Gastroenterology
; 166(5): 872-885.e2, 2024 05.
Article
in English
| MEDLINE | ID: mdl-38320723
3.
Recent progress in Lynch syndrome and other familial colorectal cancer syndromes.
CA Cancer J Clin
; 68(3): 217-231, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29485237
4.
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
Oncologist
; 28(5): 425-432, 2023 05 08.
Article
in English
| MEDLINE | ID: mdl-36807743
5.
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
J Natl Compr Canc Netw
; 21(10): 1000-1010, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37856201
6.
Clinical factors associated with skin neoplasms in individuals with Lynch syndrome in a longitudinal observational cohort.
J Am Acad Dermatol
; 88(6): 1282-1290, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36773823
7.
Serendipity Strikes: How Pursuing Novel Hypotheses Shifted the Paradigm Regarding the Genetic Basis of Colorectal Cancer and Changed Cancer Therapy.
Dig Dis Sci
; 68(9): 3504-3513, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37402979
8.
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Oncologist
; 27(4): 292-298, 2022 04 05.
Article
in English
| MEDLINE | ID: mdl-35380713
9.
Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome.
Gastroenterology
; 161(1): 143-150.e4, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33794268
10.
An updated counseling framework for moderate-penetrance colorectal cancer susceptibility genes.
Genet Med
; 24(12): 2587-2590, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36222830
11.
Risk assessment and genetic counseling for Lynch syndrome - Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.
J Genet Couns
; 31(3): 568-583, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35001450
12.
Inherited DNA-Repair Defects in Colorectal Cancer.
Am J Hum Genet
; 102(3): 401-414, 2018 03 01.
Article
in English
| MEDLINE | ID: mdl-29478780
13.
A Case of Microsatellite Instability-High Colon Cancer in a Young Woman With Familial Adenomatous Polyposis.
J Natl Compr Canc Netw
; 19(12): 1377-1381, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34902833
14.
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021.
J Natl Compr Canc Netw
; 19(10): 1122-1132, 2021 10 15.
Article
in English
| MEDLINE | ID: mdl-34666312
15.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(1): 77-102, 2021 01 06.
Article
in English
| MEDLINE | ID: mdl-33406487
16.
Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas.
N Engl J Med
; 387(18): 1714-1716, 2022 11 03.
Article
in English
| MEDLINE | ID: mdl-36322852
17.
Genetics of Familial and Sporadic Pancreatic Cancer.
Gastroenterology
; 156(7): 2041-2055, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30660730
18.
Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome.
Clin Gastroenterol Hepatol
; 18(4): 830-837.e1, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31319185
19.
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
J Natl Compr Canc Netw
; 18(4): 380-391, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32259785
20.
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Cancer
; 125(13): 2213-2221, 2019 07 01.
Article
in English
| MEDLINE | ID: mdl-30913304